Over the last twenty years fragment-based drug design (FBDD) has emerged as one of the most prominent strategies used to identify innovative drug discovery Hits. FBDD presumes drug molecules are made of a combination of small fragments, each contributing to the a nity of the drug for its biological target. Unlike HTS, which aims to identify moderate to high a nity Hits the size of a typical drug molecule, fragment screening scouts for small molecule Hits with weaker but leaner a nity to their biological target. The FDBB strategy had led to many drug discovery successes including 4 approved drugs and another 40 under clinical investigation. At Concept Life Sciences, our FBDD service is designed to enhance success rate and speed of delivery.